cyrilzakka/clinical-trials huggingface dataset:
HPV-cytology Testing Versus Cytology Testing for the Detection of High Grade CIN

To compare the effects of conventional cytology testing with concommitant HPV-cytology testing for the detection of high grade cervical lesions in primary cervical cancer screening in Hong Kong

Hypotheses:

1. There is a significant difference in the number of CIN2+ cases detected between the cytology testing group and the cytology-HPV co-testing group at baseline.
2. Significantly more CIN2+ cases will be detected at the second round of screening among participants with normal cytology result in the control arm than those with normal cytology and negative HPV results in the intervention arm.


Eligibility Criteria:
Inclusion Criteria:

* Ethnic Chinese women aged 30 to 60 years who have completed a written consent
* Women who have not attended screening for the past 3 years or more will be given priority

Exclusion Criteria:

* Currently pregnant
* Without a cervix
* Congenital abnormalities of the lower genital tract
* Previous history of invasive cervical cancer
* Who has been followed-up or treated for an abnormal cytology result in the past 12 months
* Who are unable to provide consent
Problem Solving Education and Neonatal Intensive Care Unit (NICU) Mothers

Premature infants are born at substantial risk for poor health and developmental outcomes, which commonly include hearing and vision problems, developmental delays, and poor school performance. Premature infants of low-income families face additional social risks known to worsen these outcomes. The Institute of Medicine recognized this important public health problem in its 2006 report, Preterm Birth, which argued for the need to improve the quality of follow-up care for preterm infants discharged from the neonatal intensive care unit (NICU). The underpinning of this proposal is that maternal depression - common among families of premature infants - interferes with adherence to follow-up services, and (both through this mechanism and directly) adversely impacts child health and development. Conversely, alleviating depressive symptoms among these women represents a promising strategy to improve adherence to NICU follow-up services and to improve the outcomes of this vulnerable population.

This project aims to mitigate the adverse effects of maternal depression in this specific high-risk population by testing a theory-based, parent-directed empowerment strategy, called Problem Solving Education (PSE). In the past, similar strategies have been proven effective for improving the mood and functioning of depressed adults, and for improving adherence to medical treatment. However, they have never been tested in the setting of a parent-child relationship or among families of premature infants.

This project involves a clinical trial of PSE among 50 low-income mothers at risk for depression, who have premature infants in two Boston NICUs: Boston Medical Center and Tufts Medical Center. The investigators aim to determine the impact of PSE on maternal depressive symptoms and functioning, and adherence to child health supervision and immunization schedules, vision screening, and early intervention evaluation for babies with suspected developmental delays.

Approximately 100,000 children are born prematurely to low-income families each year. Parent-directed PSE aims to improve outcomes for these children through the prevention and/or attenuation of maternal depressive symptoms, as well as through family activation and promotion of adherence to follow-up care. If successful, PSE could also provide the cornerstone of a more generalizable empowerment strategy for families of children with chronic medical conditions.


Eligibility Criteria:
Inclusion Criteria:

* Baby is ≤ 33 weeks gestational age and is expected to survive.
* Baby qualifies to receive WIC
* Mother is comfortable in English or Spanish.

Exclusion Criteria:

* Mother has psychosis
* Mother endorses suicidal ideation
* Custody of baby is uncertain
* Mother is cognitively limited, per judgment of NICU attending physician
* Baby is critically ill, per judgment of NICU attending physician
Arsha Vidya Program for Preventing Drug Abuse Among Disadvantaged Children in Urban Slums

Substance abuse remain critical problems in both developed and developing countries. Under privileged communities where health and economic system is weakest, use of drugs and illicit substances starts during adolescence and young adulthood. This not just affect physical development, mental health and social integration, but also family formation and stability, deviant behaviour, sexual behaviour and involvement, educational pursuits, livelihood pursuits. Therefore, emphasises the need for preventive education at this impressionable age.


Eligibility Criteria:
Inclusion Criteria:

* Parental consent to participate

Exclusion Criteria:

* Family not involved in de-addiction program
* Planning to move the area
* Mental incapacity to consent or participate
Effects of High Intensity Interval Training on Cognitive Flexibility Among Female Teenagers

The study suggests that the high intensity exercise training program is beneficial for the female teenagers to enhance their cognitive abilities along with the physical strengthening. It also helps the teenagers to increase their mental health for better health and memory.

The objective of the present study was to determine the effects of high-intensity interval training on cognitive flexibility among female teenagers. The current study suggests that the high intensity physical training improves the cognitive ability of the participants. Evidence indicates that regular physical activity and high intensity interval training improves the physical strengthening and corresponding improvements in cardiopulmonary physical fitness that results in the increase in cerebral perfusion and vasoreactivity across the human lifespan. The betterment in the cerebral perfusion leads to better cognitive ability and mental health.

The physical activity program comprises 8 weeks consisting of Low-intensity interval training in the first week to high-intensity interval training in the 8th week. Participants of the two groups i.e., experimental and control groups were assessed at baseline fourth and eighth week by Digital Span and Mini mental state examination.

The current study from the statistical analysis suggests that better results are obtained by high intensity physical activity among the female teenagers overtime both in terms of cognitive ability and physical strength.

Eligibility Criteria:
Inclusion Criteria:

* Participants falling in this category would be recruited into the study.

  * Female gender only
  * Age 13-19 years of female teenagers
  * Absence of serious medical or mental illness
  * volunteered to participate in this study

Exclusion Criteria:

* Participants failing to fall in this category would be excluded from the study. Diagnosed Psychiatric illness Acute or Chronic Pain and Infections Known case of bone fragility Unstable cardiovascular disease Severe cognitive, visual, or auditory impairment
A Study of LY2228820 in Participants With Advanced Cancer

The objective of this study is to determine a safe dose of LY2228820 that may be given to participants with advanced cancer. Part A of this study will consist of dose escalation, and Part B will consist of dose confirmation.


Eligibility Criteria:
Inclusion Criteria:

* Have histological or cytological evidence of a diagnosis of cancer (including lymphoma) that is advanced or metastatic disease for which no therapy of higher priority (approved therapies or therapies with published substantial evidence of effectiveness) is available, or for whom no standard therapy exists
* Have the presence of measurable or nonmeasurable disease as defined by Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
* Have adequate hematologic, renal, and hepatic organ function
* Have a performance status of less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) scale
* Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, or other investigational therapy for at least 14 days (42 days for mitomycin-C or nitrosoureas) prior to study enrollment and recovered from the acute effects of therapy
* Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial and for 3 months following the last dose of study drug
* Females with child bearing potential must have had a negative serum pregnancy test less than or equal to 7 days prior to the first dose of study drug
* Have an estimated life expectancy of ≥ 12 weeks
* Are able to swallow capsules and/or tablets

Exclusion Criteria:

* Have received treatment within 14 days of the initial dose of study drug with a drug that has not received regulatory approval for any indication
* Have a history of major surgical resection involving the stomach or small bowel, or have serious preexisting medical conditions (based on judgment of the investigator)
* Have symptomatic central nervous system malignancy or metastasis (screening is not required)
* Have a diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis)
* Have an active hematologic malignancy other than lymphoma
* Have known positive test results in human immunodeficiency virus (HIV), hepatitis B surface antigen (HBSAg), or hepatitis C antibodies (HCAb). Screening at baseline will not be required for enrollment
* Concurrent administration of any immunosuppressive therapy
* Females who are pregnant or lactating
* Have received, within 7 days of the initial dose of study drug, either grapefruit juice or treatment with a drug that is a known inhibitor or inducer of Cytochrome P450 Enzyme 3A4 (CYP3A4). In addition, participants should not receive grapefruit juice or treatment with a CYP3A4 inhibitor or inducer during the study
A Checklist (Advanced Care Planning) for The Assessment of Mobility Needs in Patients With Sarcoma

This trial tests how well the advanced care planning around mobility needs checklist tool works to assess future mobility needs in patients with sarcoma. Gathering information about sarcoma patients that have had surgery to either save or remove a limb may help doctors learn more about a patient's mobility needs. Using an advance care planning mobility needs assessment may help improve the quality of life in patients with sarcoma by helping them plan for their future mobility needs.

OUTLINE:

FIELD TEST: Participants complete the advance care planning (ACP) Mobility Checklist on study. Participants complete questionnaires at baseline and after completing the checklist intervention and undergo interview on study. Participants' medical records are also reviewed.

Eligibility Criteria:
Inclusion Criteria:

* PATIENTS: Age 18 years of age or older.
* PATIENTS: English speaking
* PATIENTS: Able to provide informed consent
* PATIENTS: Have access to a computer or other device to fill out the online checklist
* PATIENTS: Have had either limb salvage or amputation surgery for sarcoma within the last 6 months OR have metastatic (stage IV) sarcoma and are in active treatment.
* CAREGIVERS: Age 18 years of age or older
* CAREGIVERS: English speaking
* CAREGIVERS: Able to provide informed consent
* CAREGIVERS: Have access to a computer or other device to fill out the online checklist
* CAREGIVERS: The person (family member or friend) whom the patient indicates being an informal caregiver
Improving Resilience and Quality of Life of Stroke Patients

This study aims to (1) test the effect of Family System Care and Theme Care Action Module on resilience, family function, self-efficacy, and quality of life for stroke patients and their families and caregivers; and (2) interview stroke survivors (experimental group) using a semi-structured questionnaire to achieve a mix of qualitative and quantitative methodologies.

A randomized control-group pretest-posttest design was adopted. We also used a semi-structured questionnaire to qualitatively interview stroke survivors. The National Institute of Health Stroke Scale (NIHSS), Chronic Disease Self-Efficacy scales, Resilience Scale, McMaster Family Assessment Device, and Quality of Life Scale were used to test the intervention effects. Further, complex scientific concepts will be used to analyze the transition experience of stroke survivors.

Expected outcomes: The Family System Care and Theme Care Action Module can improve family function, resilience, self-efficacy, and quality of life for stroke patients and their caregivers.

Eligibility Criteria:
Inclusion Criteria:

stroke patient:

* Those who can use language expression, over 20 years old.
* Within 1-6 months of new onset; (c) Patients willing to participate. Family caregivers
* family members or relatives and friends over 20 years of age who provide the care recipients' personal needs, financial, psychological, emotional care, etc.

Exclusion Criteria:

* Aphasia
Opioid-free Anesthesia for Open Cardiac Surgery: A Prospective Randomized Controlled Trial

This study will compare an opioid free anesthetic, using dexmedetomidine, to a traditional opioid based anesthetic, using fentanyl, for patients undergoing cardiac surgery with regards to hemodynamic stability in the first 10 minutes after induction.

This is a single center, blinded, prospective, randomized controlled trial. A total of 158 subjects (79 subjects in each arm) are planned. The control group will receive a traditional cardiac anesthetic using opioids, for which induction will include fentanyl and propofol. The experimental arm will receive an opioid free anesthetic with an induction bolus of dexmedetomidine and propofol. The investigators hypothesize that using the opioid free technique will be more hemodynamically stable within the first 10 minutes of induction.

Eligibility Criteria:
Inclusion Criteria:

* Male or female ≥ 18 years of age at the time of consent.
* Undergoing non-emergent open cardiac procedures requiring cardiopulmonary bypass support, including: CABG, aortic aneurysm repair, valve repair/replacement, or CABG in combination with valve repair/replacement.
* Ability and willingness to provide written informed consent.

Exclusion Criteria:

* Chronic opioid use defined as preoperative MED \>100 daily.
* Hypersensitivity or contraindication to any of the study medications.
* Pre-existing Alzheimer's/vascular dementia.
* Pre-existing psychiatric disorder precluding ability to provide informed consent or use a visual analogue scale for pain.
* Childs-Pugh Class C liver failure or acute liver failure.
* Emergent open heart surgery, including type A aortic dissections, trauma, or conversion (bail out) from another procedure such as cardiac catheterization, ablation, transcatheter aortic valve replacement or any other general surgical procedure.
* Pregnancy or lactating.
* Inability to comply with the requirements of the study, per investigator judgment.
* Patients determined to need an awake intubation.
Umbilical Cord Length Index for Prediction of Cord Abnormalities Before Delivery

The umbilical cord plays an essential role in intrauterine life. It is the pathway between mother, placenta and fetus during pregnancy and delivery. Complete cord occlusion often leads to fetal demise, while intermittent occlusion has been associated with intrauterine brain damage. Compression and vasospasm in utero are important factors in fetal distress. Nuchal Umbilical Cord can be diagnosed antepartum using ultrasound, but the complications are unpredictable and unpreventable


Eligibility Criteria:
Inclusion Criteria:

* Singleton pregnancy.
* Pregnant ≥ 37 weeks gestation.
* Women who will accept to participate in the study

Exclusion Criteria:

* Preterm deliveries.
* Amniotic fluid abnormalities (oligohydramnios, polyhydramnios).
* Intrauterine growth retardation
* Early membrane rupture
* Women need urgent cesarean section.
* Multifetal gestation.
* Placenta previa.
* Fetuses with major congenital anomalies.
* Women with chronic maternal illness as hypertension
Effect of Crestor on Lipoprotein Metabolism in Humans

The objective of this research is to understand how Crestor can effectively reduce the levels of the bad cholesterol, LDL, in blood. It is hypothesized that with a low dose, Crestor will facilitate the rate of removal of LDL from the blood. At the higher dose, the increased potency of Crestor is explained by a reduction in the production of LDL by the liver.

Crestor has been demonstrated to be effective in reducing plasma LDL by 20 to 60% in a dose dependent fashion. While the primary mechanism of action of this class of agents is the increase in the expression of LDL receptor resulting in accelerated clearance of LDL, the increase potency of Crestor in comparison to other statins may suggest other mechanisms. We propose to study the rate of incorporation of deuterated labeled leucine into VLDL apoB and LDL apoB and to determine the effect of two doses of Crestor (5 mg/day and 40 mg/day) on the production and clearance of apoB. Participants will be admitted to the General Clinical Research Center on three occasions (4 days, 3 nights per admission) for these metabolic studies. This is an open-label study design to reflect usual care with the first admission taking place while the participant is not on any lipid-lowering therapy. The second admission will occur after a minimum of 6 weeks on the low dose (5mg/day). The dose will be increased to 40 mg/day at the time of discharge and the third admission will occur after a minimum of 6 weeks on the higher dose.

A secondary objective of this study is to examine the rate of production and clearance of apoA-I, the major protein in HDL, at the 2 doses of Crestor. In addition to a reduction in LDL, Crestor has also been reported to result in a characteristic dose-dependent increase in HDL. The mechanism of this increase is not understood.

Eligibility Criteria:
Inclusion Criteria:

* TG between 200 and 400 mg/dL
* LDLc between 160 and 250 mg/dL
* HDLc between 30 and 50 mg/dL for men and 40-65 mg/dL for women
* Lp(a) less than 30 mg/dL
* Age between 50 and 75 years

Exclusion Criteria:

* current lipid-lowering therapy,
* primary hypertriglyceridemia (TG\>400 mg/dL),
* High HDL (HDL\>70),
* high Lp(a), greater than 30 mg/dL
* presence of beta-VLDL on agarose electrophoresis,
* current use of immunosuppressive agents,
* hormone replacement therapy for women
* history of cancer, active liver disease or hepatic dysfunction (AST or ALT 1.5 x ULN (Upper Limit of Normal),
* excessive consumption of alcohol, and recent history of drug abuse.
The Additional Effect of Tongue Scraping on Halitosis Parameters in Initial Periodontal Therapy

Periodontitis can lead to tooth loss which may impair chewing ability and aesthetics. In addition, periodontitis can give rise to halitosis.

Standard initial periodontal treatment consists of supra and subgingival biofilm reduction and removal of calculus. Recently, the European Federation of Periodontology introduced clinical practice guidelines for the treatment of periodontitis. The use of a tongue scraper is not mentioned as element in the standard initial treatment of periodontitis.

We have planned a clinical study in order to provide information about the effect of standard initial periodontal therapy and the additional effect of the use of a tongue scraper as part of the oral hygiene instructions on halitosis parameters in periodontitis patients.


Eligibility Criteria:
Inclusion Criteria:

* 1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures 2. Males or females American Society of Anesthesiologist classification I of II, 3. 18 years of age or older, 4. In good general health as documented by self-assessment 5. Suffer from generalised periodontitis (according to 2018 classification) 4 6. Suffer from halitosis with suspected intra-oral cause: organoleptic score of 2 or higher by an experienced oral malodour judge 7. At least one volatile sulphur compounds measurement above the following thresholds:

  1. Portable sulphur detector \> 107 ppb 26
  2. Oral Chroma™: hydrogen sulfide (H₂S) \> 112ppb
  3. Oral Chroma™: methyl mercaptan (CH3SH) \>28ppb (as recommended by manufacturer).

Exclusion Criteria:

* 1. Participant has a history of chemotherapy or radiotherapy in head and neck area 2. Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol 3. Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial 4. Female who is pregnant, breast-feeding or has the intention of becoming pregnant in the following 6 months 5. Participation in another interventional Trial with an investigational medicinal product (IMP) or device 6. Recent intake of antibiotics (3 months prior to the first consultation) 7. Antibiotics indicated as part of the periodontal treatment 8. Use of antibiotics during the course of the study 9. Suffer from halitosis with suspected extra-oral cause 10. Suffer from a systemic disease that could cause extra-oral halitosis (e.g. diabetes mellitus, liver or kidney failure, trimethylaminuria) 11. Participant has a history of rheumatic fever, neurological deficiencies, or use of medication which may affect periodontal tissue, (phenytoin, cyclosporin, nifedipine, chronic use of non-steroidal anti-inflammatory drugs) 12. Presence of active caries lesions 13. Unwillingness to return for the follow-up examination 14. Wear partial prosthetic dentures removables 15. Participant has less than 20 teeth
Bleaching Effect of Solo and Combined Kiwi Extract and Ozone and Their Impact on Enamel

ozone therapy has been extensively used in dentistry to manage wounds healing, dental caries, oral lichen planus, gingivitis and periodontitis, halitosis, osteonecrosis of the jaw, post-surgical pain, plaque and biofilms, root canal treatment, dentin hypersensitivity, tempro-mandibular joint disorders and teeth whitening, And based on the above, in this study kiwi extract and ozone gas will be used individually and combined to evaluate the resultant effects on bleaching, enamel microhardness and micromorphology.


Eligibility Criteria:
Inclusion Criteria:

* A total of the 40 participants aged between (18-35 years) with no gender prediction.
* The participation will be entirely voluntary, and a signed statement of informed consent will be obtained prior to the start of the study.
* Systemically healthy subject based on medical and drug histories, a subject requiring scaling and polishing with moderate calculus with at least two non-adjacent hypersensitive teeth with Schiff scale scores \&gt;1 with air blast stimulus.
* Access to sound maxillary anterior teeth.
* Vitapan classical shades should be A3 or darker and lighter shades are not included.

Exclusion Criteria:

* Participants with poor oral hygiene.
* Participants with missing anterior teeth.
* Participants with unrealistic expectations.
* Participants with dental caries, those undergoing orthodontic treatment.
* Participants with a history of periodontal treatment, pregnant or lactating women and individuals with a history of asthma.
* Those who are allergic to kiwi or ozone skin therapy were excluded from the study.
* Smokers are excluded from the present study.